Introduction
============

*Staphylococcus aureus* keratitis is a significant clinical and public health concern in the United States and worldwide.[@b1-idr-12-831]--[@b3-idr-12-831] *S. aureus* is the second most frequently reported cause of bacterial keratitis with an estimated prevalence of 3%--49%. Methicillin-susceptible (MSSA) and methicillin-resistant (MRSA) *S. aureus* infections are more common following corneal transplants, contact lens wear, and cataract surgery. Rates differ by region, population sampled, and study period. Disease severity and patient outcomes are strain specific.[@b4-idr-12-831]--[@b6-idr-12-831]

In addition, increasing antibiotic resistance to fluoroquinolones and trimethoprim-- sulfamethoxazole among both MSSA and MRSA keratitis isolates poses a growing therapeutic dilemma.[@b20-idr-12-831],[@b21-idr-12-831] *S. aureus* strains differ in molecular characteristics, virulence factors, and antibiotic resistance profiles. Several studies have linked specific *S. aureus* clonal groups and lineages with particular infections, patient outcomes, and antibiotic resistance profiles.[@b7-idr-12-831]--[@b10-idr-12-831]

*S. aureus* isolates have been grouped into ten major lineages based on a combination SCC*mec*, pulsed field gel electrophoresis (PFGE), multilocus sequencing (MLST), and sequence and spa types.[@b11-idr-12-831]--[@b14-idr-12-831] Globally, *S. aureus* genotypes most frequently associated with invasive disease and postsurgical infections include clonal complex 5 (CC5)/USA100, CC30/USA200, CC8/USA300, CC1/USA400, and CC45/USA600.[@b15-idr-12-831],[@b16-idr-12-831] The most frequent healthcare-associated strains in the United States are USA100, USA200, USA500, USA600, and USA800.[@b12-idr-12-831],[@b14-idr-12-831],[@b17-idr-12-831],[@b18-idr-12-831] Healthcare-associated MRSA (HA-MRSA) strains historically contained the staphylococcal chromosomal cassette *mecA* (SCC*mecA*) genotypes I--III. The USA100 MRSA clone is the dominant healthcare-associated lineage and the leading cause of invasive infections in hospi-talized patients. Community-associated MRSA (CA-MRSA) strains traditionally contained the SCC*mecA* IV or VII genotypes.[@b12-idr-12-831],[@b18-idr-12-831] The USA300 MRSA clone is the leading cause of severe community-associated soft tissue and skin infections. Genotype and resistance profiles differ for healthcare- and community-associated *S. aureus* strains but the distinctions between the two are beginning to blur.[@b10-idr-12-831],[@b19-idr-12-831]

Few studies are available documenting the prevalence and diversity of clonal structure, virulence factors, and antibiotic resistance profiles among healthcare- or community-associated MRSA and MSSA keratitis isolates.[@b5-idr-12-831],[@b21-idr-12-831]--[@b26-idr-12-831] A better understanding of the molecular epidemiology and resistance profiles of *S. aureus* keratitis infections is essential to help decipher the changing pathology and provide further insight into selection of optimal therapy. The purpose of this study was to investigate and provide data on the prevalence and diversity of *S. aureus* genotypes and antimicrobial resistance profiles for a convenient set of *S. aureus* keratitis isolates in South Florida.

Patients and methods
====================

We used a combination of standard microbiological techniques and DNA microarray technology to characterize the epidemiology, molecular, and antibiotic resistance profiles for 47 MRSA and 28 MSSA keratitis isolates (n=75). This convenient subset of 75 isolates was selected from a group of 467 *S*. *aureus* corneal pathogens collected over an 11-year period, 2006--2016. Isolates were collected from corneal scrapings of patients presenting to our emergency room (n=45), outpatient clinics (n=27), or hospitalized patients (n=3). Standard microbiological procedures including beta hemolysis, coagulase tests, and cefoxitin screens were used to provide isolate identification and phenotype.[@b2-idr-12-831] Phenotypes were confirmed and antibiotic susceptibility patterns were determined using the Vitek 2 automated system (BioMerieux, Durham, NC, USA). Assignment of susceptible or resistance phenotype was based on standards published by the Clinical Laboratory Standards Institute.[@b27-idr-12-831]

The DNA Microarray (Alere StaphyType, Alere, Technologies GmbH, Jena, Germany) was used to genotype and classify isolates according to matched probe hybridization profiles as previously described.[@b13-idr-12-831] Briefly, the isolates are enzymatically digested and then subjected to DNA purification. A linear primer elongation reaction then amplifies and labels target sequences. This creates ssDNA aplicons that are biotin labeled and hybridized to a microarray patterned with desired oligonucleotides. DNA hybridization is then visual-ized using a streptavidin--horseradish-peroxidase conjugate that causes a subsequent precipitation of dye. The microarray is scanned and compared to the background signal.[@b13-idr-12-831] The array is a unique system that uses 333 target sequences (probes) corresponding to 170 distinct genes and their allelic variants. This allows for simultaneous detection and identification of species markers, SCC*mec* elements, toxins, CCs, virulence factors, and antibiotic resistance determinants (genes).[@b28-idr-12-831],[@b29-idr-12-831]

Keratitis isolates were defined as healthcare associated or community associated based on epidemiology and prior healthcare exposure.[@b10-idr-12-831],[@b30-idr-12-831] Healthcare-associated *S. aureus* isolates were identified as those recovered from patients with prior exposure to the healthcare system. Known risk factors among this group include ocular surface disease, prior ocular surgery, prior/prolonged topical antibiotic use, or residence in long-term care. Healthcare-associated isolates were further categorized as either healthcare-associated hospital onset (HAHO), ie, those originating in the hospital, or healthcare-associated community onset (HACO), ie, those originating from the community. Community-associated *S. aureus* keratitis isolates were those collected from patients with no recognizable healthcare exposure or known risk factors for microbial keratitis.[@b31-idr-12-831]--[@b33-idr-12-831]

Statistics
----------

Chi-squared tests and independent two-sample *t*-tests were used for comparisons between groups (MRSA vs MSSA, healthcare vs community associated). The McNemar test was used to compare phenotypic vs genotypic resistance to antimicrobials. The calculations were performed using Excel 2013 (Redman, WA, USA) and SPSS version 24 (IBM Corporation, Chicago, IL, USA). *P*-values \<0.05 were considered statistically significant.

Results
=======

Patient and isolate characterization
------------------------------------

Patient age, gender, and isolate characteristics are demonstrated in [Table 1](#t1-idr-12-831){ref-type="table"}. Among the 75 nonconsecutive *S. aureus* corneal isolates included in the study, 47 (62.7%) were phe-notyped as MRSA and the remaining 28 (37.3%) as MSSA.

[Figure 1](#f1-idr-12-831){ref-type="fig"} highlights general trends in *S. aureus* kerati-tis over a 15-year period. There was a gradual increase in the percent of corneal ulcers caused by *S. aureus* for each 5-year period; rates of *S. aureus* keratitis ranged from 11.8% (2002--2006) to 17.4% (2012--2016).

Our study population included 40 females (53.3%) and 35 males (46.7%). Patient age (n=60) ranged from 22 to 93 years with a mean of 65.1 years and a median of 67.5 years. Females (median age 74.5 years) were generally older than males (median age 56 years) and more likely to have MRSA (females: 31/40, 77.5% vs males: 16/35, 47.5%; *P=*0.0048, 95% CI: 9.79--50.13, chi-squared test). Patients with MSSA keratitis were younger (median age 60 years) and more likely to be males (males: 19/28, 67.9% vs females: 9/28, 32.1%, *P=*0.0079*,* 95% CI: 9.61--55.88, chi-squared test). The ages of 15 (20%) patients were not available; 7 of these 15 patients (46.7%) were males and 8 of 15 (53.3%) were females.

Patient setting
---------------

*S. aureus* isolates were significantly more likely to be recovered from patients presenting in the emergency room (n=45/75, 60%) than from patients visiting our outpatient clinics (n=27, 36%, *P=*0.0034, 95% CI: 8.01--38.34, chi-squared test). Twenty-two of the 27 (81.5%) isolates recovered from patients in our outpatient clinics were reported by the corneal specialty service. The remaining three (4%) isolates were isolated from hospitalized patients ([Table 1](#t1-idr-12-831){ref-type="table"}).

Clinical presentation
---------------------

Corneal ulcers were the most frequently presenting clinical diagnoses (n=30/75, 40%) followed by postsurgical infections (n=23/75, 30.7%). Twelve of 23 (52%) isolates from postsurgical infections were recovered following corneal transplants ([Table 1](#t1-idr-12-831){ref-type="table"}).

*S. aureus* isolates recovered from corneal wounds/ulcers were more likely to be methicillin-resistant (n=23/30, 76.7%) than methicillin-susceptible (n=7/30, 23.3%, *P\<*0.0001 95% CI: 28.52--69.71, chi-squared test). There was no significant difference between the proportion of MRSA isolates (n=12/23, 52.2%) and MSSA (n=11/23, 47.8%) isolates (*P*=0.9163, 95% CI: --19.3120--21.3182, chi-squared test) recovered from patients with postsurgical infections.

Healthcare- vs community-associated keratitis
---------------------------------------------

Healthcare-associated strains constituted 61/75 (81.3%) of all *S. aureus* isolates. The majority of these (58/61, 95.1%) were from the community and classified as HACO. The remaining three (4.9%) isolates were recovered from hospitalized patients and classified as HAHO. Fourteen of the 75 (18.7%) isolates were recovered from outpatients with no known healthcare exposure or microbial risk factors. These strains were classified as community associated.[@b10-idr-12-831],[@b34-idr-12-831]

The majority of the MSSA keratitis isolates (n=25/28, 89.3%) were more likely to be classified as HACO than were MRSA isolates (n=33/47, 70.2%, *P*=0.0577, 95% CI: --0.79--34.92, chi-squared test). Two of the three (66.7%) *S. aureus* isolates recovered from hospitalized patients were MRSA and both classified as HACO.

Molecular profile
-----------------

The DNA microarray identified 13 CCs, 29 strains, and 4 USA PFGE types among this group of isolates ([Table 2](#t2-idr-12-831){ref-type="table"}).

Two major USA CCs, CC5 (traditionally healthcare associated, n=30/75, 40%) and CC8 (traditionally community associated, n=28/75, 37.3%), accounted for 77.3% of the total keratitis isolates. The 47 MRSA strains clustered within the two major clones. Twenty-four or 51.1% of the isolates were identified as members of the CC5 clonal complex. The remaining 23 or 48.9% of the MRSA were classified as members of the CC8 clonal complex.

DNA microarray analysis confirmed the *mecA* genotype in 36/47 (76.6%) *S. aureus* isolates identified phenotypically as MRSA. Isolates designated as MRSA by DNA microarray (ie, *mecA* was detected) were split evenly between the CC5 clonal lineage (n=18/36, 50%) and the CC8 clonal lineage (n=18/36, 50%). Among the 18 CC5 isolates, 15/18 (83.3%) were confirmed as USA100 (traditionally HA-MRSA) and members of the ST5/225 New York--Japan clone. These possessed the classic molecular fingerprint of CC5/SCC*mec*II/ST5/t002 ([Table 2](#t2-idr-12-831){ref-type="table"}). The remaining three CC5-MRSA isolates (2.1%) included two CC5-MRSA-\[II + ACME\] clones and a single CC5-MRSA-\[II + ccrC\] strain.

Among the 18 CC8-MRSA strains, 9/18 (50%) were confirmed as USA300 (traditionally CA-MRSA) with the classic molecular fingerprint of CC8/SCC*mec*IV/ST8/t008. Additional USA-confirmed genotypes/lineages in CC8 included 4/18 (22.2%) USA500/SCC*mec*IV/ST8/t064 and one (5.5%) USA700/SCC*mec* IV/ST72/t126 isolate. The remaining four CC8-MRSA strains were epidemic MRSA stains identified as CC8-MRSA-IV-UK-EMRSA14 (n=3) and CC8-MRSA-IV, (SEA+), Lyon Clone (n=1).

Among the eleven discordant MRSA results (methicillin-resistant with no *mecA* gene detected), six isolates (54.5%) were identified as USA100 (n=3) or USA300 (n=3) deletion mutants. The remaining five isolates were classified as MSSA ([Table 2](#t2-idr-12-831){ref-type="table"}).

The 28 MSSA isolates were distributed across all 13 identified CCs. Five of these clonal complexes (CC1, CC5, CC8, CC15, and CC45) were associated with \>1 MSSA isolate and accounted for 20/28 (70.4%) of the strains. Eleven of 28 (39.3%) of MSSA strains were identified as members of either CC5 (n=6, 21.4%) or CC8 (n=5, 18.5%).

Virulence factors
-----------------

[Figure 2](#f2-idr-12-831){ref-type="fig"} highlights select virulence factors from the 75 *S. aureus* isolates. The Panton-Valentine Leucocidin (PVL) toxin (n=11, 14.7%) and *S. aureus* enterotoxin A gene (SEA, n=7, 9.3%) were both detected in MSSA and MRSA isolates. The SEA-positive isolates were most frequently associated with USA500 MRSA isolates. The Arginine Catabolic Mobile Element (ACME) was found exclusively in CC8-MRSA isolates. The USA300 MRSA clone was associated with PVL and the presence of the ACME cluster. All three genes (PVL, ACME, and enterotoxin A) were absent in the USA100 strains.

Genotype: healthcare vs community associated
--------------------------------------------

Five of the 24 (20.8%) CC5-MRSA isolates were recovered from community-associated infections while 15 of 23 (66.2%) of the CC8-MRSA isolates were recovered from infections of healthcare-associated origin. Four of the 18 (22.2%) MRSA isolates with the USA100 fingerprint were recovered from outpatients with no known healthcare exposure or risk factors for keratitis. Eleven of the 12 (91.7%) MRSA isolates characterized as USA300 were recovered from patients with known ocular healthcare risk factors. Ten of the 11 (90.9%) MRSA-USA300 isolates were classified as HACO, and one was classified as HAHO.

Resistance profiles
-------------------

[Tables 3](#t3-idr-12-831){ref-type="table"}[](#t4-idr-12-831){ref-type="table"}--[5](#t5-idr-12-831){ref-type="table"} highlight phenotypic and genotypic antibiotic resistance prevalence and patterns for the 75 *S. aureus* keratitis isolates. Phenotypic susceptibility profiles were determined for 13 antibiotics representing 11 unique antimicrobial drug classes ([Table 3](#t3-idr-12-831){ref-type="table"}). Phenotypic resistance to at least one antibiotic was detected in 63 (84%) of the 75 *S. aureus* isolates. Across all of these isolates, there were \>90% in vitro susceptibility for gentamicin (92%), linezolid (100%), and vancomycin (100%). Susceptibility for moxi-floxacin and trimethoprim-sulfamethoxazole were 33% and 89.3%, respectively.

Resistance to clindamycin (*P\<*0.0001, 95% CI: 44.69--81.58, chi-squared test) and erythromycin (*P=*0.00175, 95% CI: 3.56--40.25, chi-squared test) were higher for CC5 isolates (90% and 96.7%, respectively) than were resistance for CC8 isolates (21.4% and 75%, respectively). All USA100 and USA300 strains were resistant to erythromycin ([Table 3](#t3-idr-12-831){ref-type="table"}).

HACO strains were more likely to be resistant to erythro-mycin (43/58 or 74.1%) than community-associated isolates (9/14 or 64.2%). The rate of clindamycin resistance among USA100-MRSA isolates (18/18 or 100%) was approximately two times the rate documented for the USA300-MRSA strains (5/12 or 41.7%).

Multidrug resistance, defined as resistance to three or more classes of antibiotics, was documented for 48 or 64% of all isolates. MRSA strains (n=43/47, 91.5%) were significantly more likely to be multidrug resistant than MSSA strains (n=5/28, 17.8%, *P*\<0.0001, 95% CI: 52.71--84.91, chi-squared test). The most common phenotypic resistance pattern included co-resistance to oxacillin, ciprofloxacin, clindamycin, erythromycin, and moxifloxacin (n=24/75 or 32%, [Table 5](#t5-idr-12-831){ref-type="table"}).

The DNA microarray assay screened for the presence of 32 different resistance genes, representing 12 different antibiotic classes. Fourteen different resistance genes targeting at least eight antibiotic classes were detected among both MSSA and MRSA populations ([Table 5](#t5-idr-12-831){ref-type="table"}).

At least one antibiotic resistance gene was detected in 72 of the 75 (96%) total isolates. Three or more antibiotic resistance genes were documented in 51 (68%) of the strains. Seventy-eight percent of the isolates carried the *blaZ* gene; there was a similar distribution of the *blaZ gene* among MSSA (75%) and MRSA (80%) isolates. A high rate of genotypic resistance (88%) to fosfomycin (*fosB*) was detected among all isolates.

Genes conferring resistance to the glycopeptides (van-comycin: *vanA*, *vanB*; teicoplanin: *vanZ*), chloramphenicol (*cat*, *fexA*), oxazolidinones (linezolid: *cfr*), and fusidic acid (*far1*) were not detected among the 75 *S. aureus* isolates. The microarray did not include probes for the detection of fluoroquinolone resistance.

Correlation between phenotype and genotype
------------------------------------------

Overall agreement between phenotypic and genotypic antibiotic resistance was 94.6% with a sensitivity of 82.6% and a specificity of 99.3% ([Table 6](#t6-idr-12-831){ref-type="table"}).

Significant disagreement (*P=*0.0492, 95% CI: 0.14--30.77, McNemar's test) was observed only for the oxacillin/*mecA* pair. Forty-seven or 62.7% of all 75 *S. aureus* isolates were resistant to methicillin by phenotype while presence of the *mecA* gene was confirmed in only 36 (48%) of isolates (*P=*0.003, 95% CI: 2.51 to Infinity, McNemar's test). Agreement between the remaining antibiotic/gene pairs ranged from 89.3% to 97.3% ([Table 6](#t6-idr-12-831){ref-type="table"}).

Discussion
==========

Few studies are available documenting the genomic, phenotypic, demographic, and antibiotic profiles of healthcare- and community-associated MSSA and MRSA keratitis. This information is important because of the increasing recovery of MSSA and MRSA from surgical and nonsurgical infections. Additionally, this information is essential to help document the evolution and clonality of ocular *S. aureus* and their resistant profiles.[@b3-idr-12-831],[@b35-idr-12-831]

To our knowledge, this is the first report confirming the presence of USA100-MRSA and USA300-MRSA clones among *S. aureus* keratitis isolates in the United States. These two strains were the predominant clones circulating among keratitis isolates in South Florida.

Seventy-seven percent of the 18 USA100-MRSA strains were healthcare-associated and constituted 24% of all *S. aureus* keratitis isolates. Ninety percent of the 12 USA300-MRSA isolates were also healthcare-associated and accounted for only one (7%) of the community-associated isolates.

Hesje et al used a combination of molecular techniques including PFGE, MLST, and spa typing to characterize 40 MRSA and 16 MSSA ocular isolates collected during a 5-year period (2006--2008). Study isolates were recovered from the conjunctiva, cornea, and intraocular fluids of patients representing 24 US hospitals in 14 states.[@b24-idr-12-831] The number of keratitis isolates in this collection was not identified.

Similar to our data, two major SCC*mec* element types, II and IV, were detected among the 38 typeable MRSA isolates: twenty-two (57%) were classified as SCC*mec*II/t002 consistent with the USA100 healthcare-associated genotype and 16 (42.1%) were classified as SCC*mec*IV/t008 consistent with the USA300 genotype. All CC5/SCC*mec*II isolates were more likely to be multidrug resistant in both studies. MSSA isolates were polyclonal and belonged to 12 or more clones. Similarly, our MSSA isolates were polyclonal and distributed across 13 clonal groups.

In our study, DNA microarray confirmed the presence of the PVL toxin in 14.7% of the isolates with \>80% associated with USA300 isolates. PVL is a cytotoxic pore-forming toxin associated with USA300, skin and soft tissue infections.[@b36-idr-12-831] The role of the PVL toxin in keratitis is unclear. Zaidi et al demonstrated in general, the presence and expression of the PVL gene resulted in increased toxicity, clinical morbidity, and disease in a mouse model of keratitis.[@b36-idr-12-831] However, the overall outcome was strain and clone specific; the team reported experimental differences between the USA300 community strain compared with the USA400 strain in a mouse keratitis model. In another study, Sueke et al found that patients with PVL-positive *S. aureus* keratitis isolates were more likely to trend toward worse clinical outcomes and required more surgical interventions.[@b37-idr-12-831]

In this study, the Enterotoxin A toxin (SEA gene) was detected in seven (9.3%) of the isolates. Greater than 50% of these isolates were associated with the USA500 MRSA clone, the progenitor of the current USA300 epidemic MRSA strain.[@b38-idr-12-831],[@b39-idr-12-831] The USA500 MRSA clone is frequently associated with invasive disease in the USA. This is the first report of SEA-positive MRSA keratitis isolates.

Fujishima et al demonstrated a link between *S. aureus* enterotoxins and corneal ulceration in 11 patients with atopic keratoconjunctivitis.[@b40-idr-12-831] *S. aureus* enterotoxin B (SEB) was detected in two (18.2%) *S. aureus* isolates, enterotoxin G (SEG) in eight (72.7%) isolates, and enterotoxin I (SEI) in eight (72.7%) isolates. No SEA strains were detected among the 11 *S. aureus* isolates.[@b40-idr-12-831]

The ACME, a virulent factor contributing to enhanced growth and invasiveness of USA300 MRSA, was present in 13 of our isolates. All of the ACME-positive isolates were associated with the USA300 MRSA clone.

Our in vitro susceptibility data differed from those reported in a 20-year study of *S. aureus* keratitis isolates by Chang et al.[@b41-idr-12-831] Specifically, there was a difference in the rates of resistance among healthcare- and community-associated MSSA and MRSA keratitis isolates to the fourth generation fluoroquinolones and gentamicin. In our study, 85% of our community-associated *S. aureus* isolates and 61% of our healthcare-associated isolates were resistant to moxifloxacin. Ninety-one percent of MRSA isolates and 18% of MSSA isolates were resistant to moxifloxacin. Only vancomycin (100%) and gentamicin (92%) provided in vitro susceptibilities of ≥90%.

In contrast, the Chang et al study reported only 35% of MRSA and 6% of MSSA isolates resistant to moxifloxacin.[@b41-idr-12-831] Thirteen percent of MRSA isolates and 2.2% of MSSA isolates in the Chang et al study were resistant to gentamicin, while our study reported less than 10% gentamicin resistance for both MRSA (8%) and MSSA (7%). Similar to our study, resistance rates were higher for MRSA than for MSSA isolates.

Agreement between susceptible/resistant phenotype as determined by the Vitek 2 and detection of the corresponding resistance gene determinants was \>90% for erythromycin, clindamycin, gentamicin, linezolid, tetracycline, trimethoprim--sulfamethoxazole, and vancomycin for the 75 *S. aureus* isolates. The *mecA* gene was present in only three-quarters (76.6%) of the 47 isolates identified phenotypically as MRSA. The *mecC* gene was negative in all isolates. These genes (*mecA, mecC*) reside on the mobile SCC*mec* genetic element and code for an alternative penicillin binding protein (PBP2a) with low affinity for broad-spectrum beta-lactam antibiotics. Expression is heterogeneous and variable. Several reports have identified *mecA*-negative, methicillin-resistant isolates, as the resistance mechanism can be independent of the *mecA* gene. Methicillin-resistant, *mecA*-negative strains may confer beta-lactam resistance via intrinsic chromosomal mutations, beta-lactamase hyper production, production of methicillinases, and presence of small colony variants.[@b10-idr-12-831],[@b17-idr-12-831],[@b42-idr-12-831]--[@b44-idr-12-831]

The *blaZ* gene, which confers resistance to penicillin, was detected in \>70% of the MSSA and MRSA keratitis isolates. Rates of detection of resistance determinants for the aminoglycosides tobramycin (*aadD*), kanamycin (*aphA3*), and neomycin (*aphA3*) were three to four times higher than the rate of detection for the gentamicin resistance determinant (*aacA-aphD*). Fifteen percent of the study isolates possessed the *mupR* gene conferring resistance to mupirocin; the rate was twice as high for MRSA isolates compared with detection rate for the MSSA isolates. Interestingly, the most prevalent resistance determinant among the study group was *fosB*, conferring resistance to the fosfomycin. The gene was detected in 100% of MRSA isolates and two-thirds of the MSSA isolates. Taken together, our data confirm a high prevalence of resistance gene determinants among *S. aureus* and support the use of molecular methods such as DNA microarray technology for their simultaneous detection.[@b28-idr-12-831]

Conclusion
==========

USA100 and USA300 MRSA clones were common among South Florida keratitis isolates. The shifting and increasing rates of antibiotic resistance among these two clones, as well as among MSSA isolates, are a cause for concern. Understanding the molecular characteristics of *S. aureus* keratitis may offer insights into this changing epidemiology and support for the development of new treatment strategies.

Limitations
-----------

Our study has several limitations. First, it is a retrospective study and contains a small subset of the total isolates collected during the 11-year period. Analysis of all *S. aureus* isolates from this time period could offer different results. Second, these results are reported from a single institution and may not be generalizable to other parts of the United States or the world. Nevertheless, we offer the first documentation of the intermixing of healthcare- and community-associated MRSA and MSSA among *S. aureus* keratitis isolates in South Florida. We also confirm the presence of high levels of genetic resistance to common ocular antibiotics, which has implications for patient management and institutional infection control strategies. The cumulative data suggest that vancomycin and gentamicin may provide broader in vitro susceptibility for the management of *S. aureus* keratitis in South Florida. Taken together, we provide an early "snapshot" of the evolving epidemiology, molecular characteristics, and antibiotic resistance of *S. aureus* keratitis isolates in South Florida.
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![Trends in *Staphylococcus aureus* keratitis 2002--2016.\
**Notes:** This figure highlights the prevalence of *S. aureus* keratitis presenting at Bascom Palmer Eye Institute over a 15-year period (which includes the 11-year study period in which the 75 *S*. *aureus* isolates were collected). The percentage corneal ulcers from which *S. aureus* was recovered increased from 11.8% to 17.4% over the study period. In contrast, the prevalence of MRSA isolates decreased by 4.7%.\
**Abbreviation:** MRSA, methicillin-resistant *Staphylococcus aureus*.](idr-12-831Fig1){#f1-idr-12-831}

![Frequency and distribution of select virulence genes detected among *Staphylococcus aureus* keratitis isolates.\
**Notes:** Virulence genes associated with increased invasiveness and pathology were more frequently associated with the USA300 MRSA clone. The ACME pathogenic island clusters were identified exclusively in MRSA isolates, while the PVL toxin and enterotoxin A genes were also present in at least 3.6% of MSSA isolates.\
**Abbreviations:** ACME, arginine catabolic mobile element associated with increased skin colonization, invasion, and *S. aureus* fitness; MRSA, methicillin-resistant *S. aureus*; MSSA, methicillin-susceptible *S. aureus*; PVL, Panton-Valentine Leukocidin, a cytotoxic, pore-forming toxin most commonly associated with pulse field electrophoresis type USA300, SEA, *S. aureus* enterotoxin A gene (enterotoxin associated with food poisoning and increased proinflammatory cytokine production).](idr-12-831Fig2){#f2-idr-12-831}

###### 

Patient demographics and general isolate characteristics

  Patient/isolate characteristics                                               MRSA (n=47)   MSSA (n=28)   Total (n=75)
  ----------------------------------------------------------------------------- ------------- ------------- --------------
  Gender                                                                                                    
   Females                                                                      31            9             40 (53.3)
   Males                                                                        16            19            35 (46.7)
  Age groups                                                                                                
   20--39                                                                       3             4             7 (9.3)
   40--59                                                                       6             9             15 (20.0)
   60--79                                                                       12            8             20 (26.7)
   80--99                                                                       12            6             18 (24.0)
   Unknown                                                                      14            1             15 (20.0)
  Patient settings[a](#tfn1-idr-12-831){ref-type="table-fn"}                                                
   Outpatients-ER                                                               27            18            45 (60.0)
   Outpatients-non ER Clinics                                                   18            9             27 (36.0)
   Inpatients                                                                   2             1             3 (4.0)
  Diagnosis/risk factors                                                                                    
   Corneal ulcer                                                                23            7             30 (40.0)
   CTL-associated keratitis                                                     3             3             6 (8.0)
   Ocular surface disorders[b](#tfn2-idr-12-831){ref-type="table-fn"}           5             6             11 (14.7)
   Postsurgical (ocular) infections[c](#tfn3-idr-12-831){ref-type="table-fn"}   12            11            23 (30.7)
   Recurrent MRSA/MSSA keratitis                                                4             1             5 (6.7)
  Epidemiology                                                                                              
   Healthcare associated[d](#tfn4-idr-12-831){ref-type="table-fn"}              35            26            61 (81.3)
   Community associated^e^                                                      12            2             14 (18.7)

**Notes:**

Settings -- ER: emergency room; non-ER clinics: external, retina, plastics, resident.

Ocular surface disease -- one case each of bullous keratopathy, epithelial defect, keratoconus, cornea edema, corneal burn, corneal abrasion, and five cases of ocular surface disease, unspecified.

Postsurgical ocular infections -- post-penetrating keratoplasty (n=12), post-cataract (n=4), post-LASIK (n=3), and post-ocular surgery unspecified (n=4).

Healthcare associated -- HAHO (n=3 or 4.9%) and HACO (n=58 or 95.1%). ^e^Community associated -- community-associated community onset.

**Abbreviations:** CTL, contact lens; ER, emergency room; HACO, healthcare-associated community onset; HAHO, healthcare-associated hospital onset; MRSA, methicillin-resistant *Staphylococcus aureus*; MSSA, methicillin-susceptible *Staphylococcus aureus*.

###### 

DNA microarray assignment of clonal complexes and strain affiliation for *Staphylococcus aureus* keratitis isolates

  Clonal complex                                                         Strain genotype assignment[a](#tfn6-idr-12-831){ref-type="table-fn"}    Phenotype        
  ---------------------------------------------------------------------- ----------------------------------------------------------------------- ----------- ---- ----
  CC1                                                                    CC1-MSSA                                                                0           2    2
  CC5                                                                    CC5-MRSA-\[II + ACME\]                                                  2           0    2
  CC5-MRSA-\[II + ccrC\]                                                 1                                                                       0           1    
  CC5-MSSA                                                               2                                                                       6           8    
  CC5-MSSA-ACME                                                          1                                                                       0           1    
  CC5-MSSA, possibly, a deletion mutant of ST5/ST225-MRSA II, USA100     3                                                                       0           3    
  CC5-ST5/ST225-MRSA, Rhine-Hesse EMRSA, New York--Japan Clone, USA100   15                                                                      0           15   
  CC5-Total                                                              24                                                                      6           30   
  CC6                                                                    CC6-MSSA                                                                0           1    1
  CC8                                                                    CC8-MRSA-IV (PVL+), ACME-, Spanish or Latin America variant of USA300   2           0    2
  CC8-MRSA-IV (SEA+), Lyon Clone/UK EMRSA 2                              1                                                                       0           1    
  CC8-MRSA-IV, UK-EMRSA-14/WA-MRSA-5                                     3                                                                       0           3    
  CC8-MRSA-IV, USA500                                                    4                                                                       0           4    
  CC8-MSSA                                                               1                                                                       2           3    
  CC8-MSSA \[PVL+\]                                                      1                                                                       1           2    
  CC8-MSSA-\[ACME\] (PVL+)                                               0                                                                       1           1    
  CC8-MSSA-\[ACME\] (PVL+), possibly, a deletion mutant of USA300        3                                                                       0           3    
  CC8-ST8-MRSA-\[IV + ACME\] (PVL+), USA300                              3                                                                       0           3    
  CC8-ST8-MRSA-\[IV + ACME\], putative PVL-, deletion mutant of USA300   4                                                                       0           4    
  CC8-ST72-MRSA-IV, USA700                                               1                                                                       0           1    
  CC8-ST72-MSSA                                                          0                                                                       1           1    
  CC8-Total                                                              23                                                                      5           28   
  CC9                                                                    CC9-MSSA                                                                0           1    1
  CC15                                                                   CC15-MSSA                                                               0           3    3
  CC25                                                                   CC25-MSSA                                                               0           1    1
  CC30                                                                   CC30-MSSA                                                               0           1    1
  CC45                                                                   CC45-MSSA                                                               0           4    4
  CC97                                                                   CC97-MSSA                                                               0           1    1
  CC121                                                                  CC121-MSSA                                                              0           1    1
  CC188                                                                  CC188-MSSA                                                              0           1    1
  CC398                                                                  CC398-MSSA                                                              0           1    1
                                                                         TOTAL                                                                   47          28   75

**Notes:**

Strain genotype and clonal complex assignments determined by DNA microarray (Alere StaphyType, Alere Technologies GmbH, Jena, Germany).

**Abbreviations:** II, SCC*mec*II--staphylococcus chromosomal cassette type II; IV, SCC*mec*IV--staphylococcus chromosomal cassette type IV; ACME, arginine catabolic mobile element (increases skin colonization, invasion and fitness of *S. aureus* isolates); ccrC, cassette chromosome recombination C gene leads to variants of SCC*mec* gene in *S. aureus*; EMRSA, epidemic MRSA strain; MRSA, methicillin-resistant *S. aureus*; MSSA, methicillin-susceptible *S. aureus*; PVL, Panton-Valentine Leucocidin--cytotoxin associated with USA300 PFGE-type; SEA+, *S. aureus* enterotoxin A gene; UK, United Kingdom; USA, United States of America; WA, Western Australia.

###### 

Phenotypic resistance among *Staphylococcus aureus* keratitis isolates

                                                      \% Resistant (nonsusceptible)[a](#tfn8-idr-12-831){ref-type="table-fn"}                         
  ------------------ -------------------------------- ------------------------------------------------------------------------- ------- ------------- -------------
  Aminoglycosides    Gentamicin                       8.0                                                                       8.5     7.1           *P*=0.8298
  Beta-lactams       Oxacillin (methicillin)          62.7                                                                      100.0   0             NA
  Fluoroquinolones   Ciprofloxacin                    65.3                                                                      93.6    17.8          *P*\<0.0001
  Levofloxacin       65.3                             93.6                                                                      17.8    *P*\<0.0001   
  Moxifloxacin       63.5                             91.3                                                                      17.8    *P\<*0.0001   
  Glycopeptides      Vancomycin                       0                                                                         0       0             1
  Lincosamides       Clindamycin                      52                                                                        63.8    32.1          *P*=0.0083
  Lipopeptides       Daptomycin                       0                                                                         0       0             1
  Macrolides         Erythromycin                     73.3                                                                      89.4    46.4          *P*=0.0001
  Oxazolidinones     Linezolid                        0                                                                         0       0             1
  Sulfonamides       Trimethoprim--sulfamethoxazole   10.7                                                                      14.9    3.6           *P*=0.1280
  Tetracyclines      Tetracycline                     16.0                                                                      12.8    21.4          *P*=0.3292

**Notes:**

\% resistant includes both intermediate and resistant isolates.

Number tested as indicated except for moxifloxacin (total, n=74; MRSA, n=47; MSSA, n=27); daptomycin (total, n=59; MRSA, n=34; MSSA, n=25); and linezolid (total, n=73; MRSA, n=46; MSSA, n=27).

Phenotype determined by cefoxitin screen, Vitek 2 (BioMerieux, Raleigh, NC, USA).

*P-*value calculated using the chi-squared test, Excel 2013 (Microsoft Corporation, Redmond, WA, USA). Significance set at α=0.05.

**Abbreviations:** MRSA, methicillin-resistant *S. aureus*; MSSA, methicillin-susceptible *S. aureus*.

###### 

Diversity and frequency of antibiotic resistance determinants (genes) among *Staphylococcus aureus* keratitis isolates

  Resistant genotype (Gene)   Antibiotic target                                                                                          Phenotypes          
  --------------------------- ---------------------------------------------------------------------------------------------------------- ------------ ------ ------
  *aacA-aphD*                 Gentamicin                                                                                                 8.0          8.5    7.1
  *aadD*                      Tobramycin[a](#tfn13-idr-12-831){ref-type="table-fn"}                                                      24.0         36.2   3.6
  *aphA3*                     Kanamycin[a](#tfn13-idr-12-831){ref-type="table-fn"} Neomycin[a](#tfn13-idr-12-831){ref-type="table-fn"}   36.0         40.4   28.6
  *mecA*                      Oxacillin (Methicillin)                                                                                    48           76.6   0
  *blaZ*                      Penicillins[a](#tfn13-idr-12-831){ref-type="table-fn"}                                                     78.7         80.8   75
  *ermA*                      Clindamycin Erythromycin                                                                                   41.3         51.1   25.0
  *ermC*                      Clindamycin Erythromycin                                                                                   5.3          4.3    7.1
  *mpbBM*                     Clindamycin Erythromycin                                                                                   38.7         48.9   21.4
  *mrsA*                      Erythromycin                                                                                               38.7         48.9   21.4
  *fosB*                      Fosfomycin[a](#tfn13-idr-12-831){ref-type="table-fn"}                                                      88.0         100    67.8
  *mupR*                      Mupirocin[a](#tfn13-idr-12-831){ref-type="table-fn"}                                                       14.7         19.1   7.1
  *Sat*                       Streptothricin[a](#tfn13-idr-12-831){ref-type="table-fn"}                                                  36.0         40.4   28.6
  *dfrA*                      Trimethoprim                                                                                               5.3          6.4    3.6
  *tetK*                      Tetracycline                                                                                               5.3          0      14.3
  *tetM*                      Tetracycline                                                                                               6.7          6.4    7.1

**Note:**

Not tested using phenotypic techniques.

**Abbreviations:** *aacA-aphD*, aminoglycoside modifying bifunctional-adenylphosphotransferase enzyme includes both intermediate and resistant isolates (gentamicin, tobramycin); *aadD*, aminoglycoside adenyltransferase enzymes (neomycin, kanamycin, and/or tobramycin); *aphA3*, bifunctional aminoglycoside phosphotransferase, modifying enzyme (neomycin kanamycin); *blaZ*, beta-lactamase gene (penicillins); *dfrA*, dihydrofolate reductase mediating trimethoprim resistance; *ermA*, rRNA methyltransferase associated with macrolide/lincosamide resistance; *ermC*, rRNA methyltransferase associated with macrolide/lincosamides resistance; *fosB*, metallothiol transferase; *mecA*, penicillin binding protein 2a (an SCC element, confers resistance to most beta-lactams); *mpbBM*, macrolide phosphotransferase II; *mrsA*, macrolide efflux pump; *mupR*, isoleucyl-tRNA synthetase associated with mupirocin resistance; MRSA, methicillin-resistant *S. aureus*; MSSA, methicillin-susceptible *S. aureus*; *sat*, streptothricin acetyltransferase; *tetK*, tetracycline efflux protein, and *tetM*, ribosomal protection protein associated with tetracycline resistance*.*

###### 

Comparison of resistant phenotype expression and resistant genotype among *Staphylococcus aureus* keratitis isolates

  Number of isolates/% of total *S. aureus* isolates (n=75)             Resistant phenotypic (antibiotic) profile[a](#tfn16-idr-12-831){ref-type="table-fn"}   Resistant genotypic (genes) profile[b](#tfn17-idr-12-831){ref-type="table-fn"}   Epidemiology[c](#tfn18-idr-12-831){ref-type="table-fn"}                                                                                                                                                                          
  --------------------------------------------------------------------- -------------------------------------------------------------------------------------- -------------------------------------------------------------------------------- --------------------------------------------------------- ------ ------- ------- ------- ------- --------------------------------------------------------------------------------------------------------------------------- --- ---
  Methicillin-susceptible isolates                                                                                                                                                                                                                                                                                                                                                                                                                                               
  12 (16%)                                                                                                                                                                                                                                                                                                                                       None detected                                                                                                               3   1
  *blaZ*                                                                2                                                                                                                                                                                                                                                                                                                                                                                                        
  *blaZ, fosB*                                                          5                                                                                      1                                                                                                                                                                                                                                                                                                                 
  2 (2.7%)                                                                                                                                                                                                                                                                                                                                       *blaZ, msrA, mphBM, aphA3, sat, mupA, tetK, fosB*                                                                           1   
  *blaZ, msrA, mphBM, aphA3, sat, fosB*                                 1                                                                                                                                                                                                                                                                                                                                                                                                        
  2 (2.7%)                                                                                                                                                                                                                                                                                                                                       *blaZ, aphA3, sat, tetK, fosB*                                                                                              2   
  5 (6.7%)                                                                                                                                                                                                                                                                                                                                       *blaZ*                                                                                                                      1   
  *blaZ, ermA*                                                          1                                                                                                                                                                                                                                                                                                                                                                                                        
  *blaZ, ermA, fosB*                                                    2                                                                                                                                                                                                                                                                                                                                                                                                        
  *ermC, fosB*                                                          1                                                                                                                                                                                                                                                                                                                                                                                                        
  1 (1.3%)                                                                                                                                                                                                                                                                                                                                       *ermA*                                                                                                                      1   
  1 (1.3%)                                                                                                                                                                                                                                                                                                                                       *blaZ*, *msrA*, *mphBM, aphA3, sat, fosb*                                                                                   1   
  1 (1.3%)                                                                                                                                                                                                                                                                                                                                       *blaZ, ermA, aad, fosB*                                                                                                     1   
  1 (1.3%)                                                                                                                                                                                                                                                                                                                                       *blaZ, msrA, mphBM, aphA3, sat, mupA, tetK, fosB*                                                                           1   
  1 (1.3%)                                                                                                                                                                                                                                                                                                                                       *ermA, aacA-aphD, aphA3, sat, tetK*                                                                                         1   
  1 (1.3%)                                                                                                                                                                                                                                                                                                                                       *ermA, ermC, tetM, fosb*                                                                                                    1   
  1 (1.3%)                                                                                                                                                                                                                                                                                                                                       *blaZ, msrA, mphBM, aacA-aphD, aph3, sat, dfrA, mupA, tetM, fosB*                                                           1   
  28 (37.3%)                                                            Total methicillin-susceptible isolates                                                                                                                                  26                                                        2                                                                                                                                                                      
  \% Resistant                                                          46.4%                                                                                  17.8%                                                                            32.1%                                                     7.1%   17.8%   3.6%    21.4%   0%      \% MSSA isolates resistant to three or more antibiotic classes: phenotype, n=5 (17.8%); genotype, n=12 (42.8%)                  
  MRSA isolates                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
  1 (1.3%)                                                                                                                                                                                                                                                                                                                                       *mecA, blaZ, fosB*                                                                                                          1   
  2 (6.7%)                                                                                                                                                                                                                                                                                                                                       *mecA, blaZ, msrA, mphBM, aphA3, sat, fosB*                                                                                 1   
  *fosB*                                                                1                                                                                                                                                                                                                                                                                                                                                                                                        
  1 (1.3%)                                                                                                                                                                                                                                                                                                                                       *mecA, blaZ, msrA, mphBM, aphA3, sat, fosB*                                                                                     1
  1 (1.3%)                                                                                                                                                                                                                                                                                                                                       *blaZ, fos*                                                                                                                     1
  5 (6.7%)                                                                                                                                                                                                                                                                                                                                       *fosB*                                                                                                                      2   
                                                                        *mecA, blaZ, msrA, mphBM, aphA3, sat, fosB*                                            3                                                                                                                                                                                                                                                                                                                 
  1 (1.3%)                                                                                                                                                                                                                                                                                                                                       *mecA, blaZ, msrA,mphBM, aphA3, fosB*                                                                                       1   
  2 (2.7%)                                                                                                                                                                                                                                                                                                                                       *mecA, blaZ, fosB*                                                                                                          2   
  24 (32%)                                                                                                                                                                                                                                                                                                                                       *ermA, fosB*                                                                                                                    2
  *blaZ, ermA, fosB*                                                    2                                                                                                                                                                                                                                                                                                                                                                                                        
  *ermA, aad, fosB*                                                     1                                                                                                                                                                                                                                                                                                                                                                                                        
  *mecA, blaZ, ermA, fosB*                                              2                                                                                                                                                                                                                                                                                                                                                                                                        
  *mecA, blaZ, ermA, aadD, fosB*                                        2                                                                                                                                                                                                                                                                                                                                                                                                        
  *mecA, msrA, aac, mupA dfrA, fosB*                                                                                                                           1                                                                                                                                                                                                                                                                                                                 
  *mecA, blaZ, ermA,, aadD, mupA, fosB*                                 1                                                                                                                                                                                                                                                                                                                                                                                                        
  *mecA, blaZ, ermA, msrA, aadD, sat, fosB*                             1                                                                                                                                                                                                                                                                                                                                                                                                        
  *mecA, blaZ, msrA, mphBM, aphA3, sat, fosB*                           2                                                                                                                                                                                                                                                                                                                                                                                                        
  *mecA, blaZ, ermA, msrA, mphBM, aad, mupA, fosB*                      1                                                                                                                                                                                                                                                                                                                                                                                                        
  *mecA, blaZ, ermA, msrA, mphBM, aadD, aphA3, sat, fosB*               2                                                                                      2                                                                                                                                                                                                                                                                                                                 
  *mecA, blaZ, ermA, msrA, mphBM, aadD, mupA, sat, fosB*                1                                                                                                                                                                                                                                                                                                                                                                                                        
  *mecA, blaZ, ermA, msrA, mphBM, aacA-aphD, aph3, sat, fosB*           1                                                                                                                                                                                                                                                                                                                                                                                                        
  *mecA, blaZ, ermA, msrA, mphBM, aadD, aphA3, sat, mupA, fosB*         1                                                                                                                                                                                                                                                                                                                                                                                                        
  *mecA, blaZ, ermA, msrA, mphBM, aadD, aphA3, sat, dfrA, mupA, fosB*   1                                                                                                                                                                                                                                                                                                                                                                                                        
  1 (1.3)                                                                                                                                                                                                                                                                                                                                        *mecA ,blaZ, ermC, msrA, mphBM, aphA3, sat, fosB*                                                                           1   
  1 (1.3)                                                                                                                                                                                                                                                                                                                                        *ermA, fosB*                                                                                                                    2
  1 (1.3                                                                                                                                                                                                                                                                                                                                         *mecA, blaZ, msrA, mphBM, aphA3, sat, fosB*                                                                                     1
  1 (1.3)                                                                                                                                                                                                                                                                                                                                        *mecA, blaZ, fosB*                                                                                                              1
  1 (1.3)                                                                                                                                                                                                                                                                                                                                        *mecA, blaZ, msrA, mphBM, aacA-aphD, aphA3, sat, mupA, tetM, fosB*                                                          1   
  1 (1.3)                                                                                                                                                                                                                                                                                                                                        *mecA, blaZ, msrA, mphBM, aadD, sat, mupA, fosB*                                                                                1
  1 (1.3)                                                                                                                                                                                                                                                                                                                                        *mecA, blaZ, msrA, mphBM, aacA-aphD, aphA3, sat, dfrA, mupA, tetM, fosB*                                                    1   
  1 (1.3)                                                                                                                                                                                                                                                                                                                                        *mecA, fosB*                                                                                                                1   
  1 (1.3)                                                                                                                                                                                                                                                                                                                                        *mecA, blaZ, msrA, mphBM, aacA-aphD, aphA3, sat, dfrA, mupA, tetM, fosB*                                                    1   
  1 (1.3%)                                                                                                                                                                                                                                                                                                                                       *blaZ, ermC, fosB*                                                                                                          1   
  47 (62.7%)                                                                                                                                                   TOTAL                                                                            35                                                        12                                                                                                                                                                     
  \% MRSA resistant                                                     89.4%                                                                                  93.6%                                                                            63.8%                                                     8.5%   91.3%   14.9%   12.8%   100%    \% MRSA isolates resistant to three or more antibiotic classes Phenotype, n=43 (91.5%); genotype, 39 (83.0%)                    
  \% Resistant All isolates (n=75)                                      73.3%                                                                                  65.3%                                                                            63.8%                                                     8.0%   63.5%   10.7%   16.0%   62.7%   \% of all *S. aureus* isolates resistant to three or more antibiotic classes: Phenotype, n=48 (64%); genotype, n=51 (68%)       

**Notes:** Comparative profiles were available for eight antibiotics/pairs. These included ciprofloxacin, clindamycin, erythromycin, gentamicin, moxifloxacin, trimethoprim-sulfamethoxazole, tetracycline and oxacillin. Among the resistant group, agreement ranged from 76% for methicillin to 97.6% for gentamicin. No isolates were resistant to linezolid and/or vancomycin by phenotype and/or by the presence of resistant genes.

Resistant phenotypic profile:

Resistant genotypic profile:

HA, healthcare associated. Phenotypic resistant pattern key:

**Abbreviations:** CIP, ciprofloxacin, CLI, clindamycin; ERY, erythromycin; GM, gentamicin; MOX, moxifloxacin; OX, oxacillin; SXT, trimethoprim sulfamethoxazole; TET, tetracycline; *aacA-aphD*, aminoglycoside modifying bifunctional-adenylphosphotransferase enzyme includes both intermediate and resistant isolates (gentamicin, tobramycin); *aadD*, aminoglycoside adenyltransferase enzymes (neomycin, kanamycin, and/or tobramycin); *aphA3*, bifunctional aminoglycoside phosphotransferase, modifying enzyme (neomycin kanamycin); *blaZ*, beta-lactamase gene (penicillins); *dfrA*, dihydrofolate reductase mediating trimethoprim resistance; *ermA*, rRNA methyltransferase associated with macrolide/lincosamide resistance; *ermC*, rRNA methyltransferase associated with macrolide/lincosamides resistance; *fosB*, metallothiol transferase (fosfomycin B); *mecA*, penicillin binding protein 2a (an SCC element resistance to most beta-lactams); MRSA, methicillin-resistant *S. aureus*; *mpbBM*, macrolide phosphotransferase II; *mrsA*, macrolide efflux pump; *mupR*, isoleucyl-tRNA synthetase associated with mupirocin resistance; *sat*, streptothricin acetyltransferase; *tetK*, tetracycline efflux protein, and *tetM,* ribosomal protection protein associated with tetracycline resistance; CA, community associated.

###### 

Correlation between resistance phenotype and genotype among *Staphylococcus aureus* keratitis

  Antibiotic vs gene determinant(s)                       MRSA isolates (n=47)   MSSA isolates (n=28)   Total isolates (n=75)   Sensitivity (total isolates) (%)   Specificity (total isolates) (%)   *P*-value McNemar (phenotype vs genotype)
  ------------------------------------------------------- ---------------------- ---------------------- ----------------------- ---------------------------------- ---------------------------------- -------------------------------------------
                                                                                                                                                                                                      
  Oxacillin vs *mecA*                                     76.6                   100.0                  85.3                    76.6                               100.0                              0.0026
  Clindamycin total vs *ermA, ermB, ermC, linA*           91.5                   100.0                  94.7                    87.2                               100.0                              0.0736
  Erythromycin vs *ermA, ermB, ermC, msrA, mefA, mpbBM*   91.5                   89.3                   90.7                    90.9                               90.0                               0.4497
  Gentamicin vs *aacA-aphD*                               95.7                   100.0                  97.3                    83.3                               98.6                               0.4795
  Tetracycline vs *tetK, tetM*                            93.6                   100.0                  96.0                    75.0                               100.0                              0.2482
  Trimethoprim--sulfamethoxazole vs *dfrA*                91.5                   100.0                  94.7                    50.0                               100.0                              0.1336
  Total antibiotic/gene pairs                                                    94.6                   82.6                    99.3                               0.00001                            

**Notes:** This table shows the correlation between screened resistance genes and evaluated antibiotics. Overall agreement ranged from 85.3% for oxacillin to 97.3% for gentamicin. Agreement between oxacillin and *mecA* for MRSA was 76.6%. For MSSA, correlation between erythromycin resistance and presence of macrolide resistance determinants was 89.3%. All isolates were susceptible to vancomycin and linezolid by phenotype and genotype.

**Abbreviations:** *aacA-aphD*, aminoglycoside modifying bifunctional-adenylphosphotransferase enzyme; *dfrA*, dihydrofolate reductase mediating trimethoprim resistance; *ermA*, rRNA methyltransferase associated with macrolide/lincosamide resistance; *ermB*, rRNA methyltransferase associated with macrolide/lincosamide resistance; *ermC*, rRNA methyltransferase associated with macrolide/lincosamide resistance; *linA*, lincosamide nucleotidyltransferase gene conferring resistance to clindamycin; *mecA*, penicillin binding protein PBP2a, SCC element, confers resistance to most beta-lactams; *mefA*, macrolide efflux pump; *mpbBM*, macrolide phosphotransferase II; *mrsA*, macrolide efflux pump; MRSA, methicillin-resistant *S. aureus*; MSSA, methicillin-susceptible *S. aureus*; *tetK*: tetracycline efflux protein, and *tetM*: ribosomal protection protein associated with tetracycline resistance,..
